(S)-N¹-((S)-1-Benzyl-2-{(S)-2-[(1S,2S)-1-((S)-1-carbamoyl-2-methyl-propylcarbamoyl)-2-methyl-butylcarbamoyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-(2-oxo-acetylamino)-succinamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N¹-((S)-1-Benzyl-2-{(S)-2-[(1S,2S)-1-((S)-1-carbamoyl-2-methyl-propylcarbamoyl)-2-methyl-butylcarbamoyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-(2-oxo-acetylamino)-succinamide
• 英文别名: (2S)-N-[(1S)-1-benzyl-2-[(2S)-2-[[(1S,2S)-1-[[(1S)-1-carbamoyl-2-methyl-propyl]carbamoyl]-2-methyl-butyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-ethyl]-2-(oxaldehydoylamino)butanediamide；(2S)-N-[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-2-(oxaldehydoylamino)butanediamide
• 化学式: C₃₁H₄₅N₇O₈
• 分子量: 643.74
• InChiKey: QLKNPVHBYSLIJK-HCAOAXFJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  46
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  240
• 氢给体数：
  6
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (S)-N¹-((S)-1-Benzyl-2-{(S)-2-[(1S,2S)-1-((S)-1-carbamoyl-2-methyl-propylcarbamoyl)-2-methyl-butylcarbamoyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-(2,2-bis-isopropylsulfanyl-acetylamino)-succinamide 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 水 、 乙腈 为溶剂， 反应 1.0h， 生成 (S)-N¹-((S)-1-Benzyl-2-{(S)-2-[(1S,2S)-1-((S)-1-carbamoyl-2-methyl-propylcarbamoyl)-2-methyl-butylcarbamoyl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-(2-oxo-acetylamino)-succinamide
  参考文献：
  名称：

  Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors

  摘要：

  A series of novel synthetic peptides containing an N-terminal glyoxylyl function (CHOCO-) have been tested as inhibitors of HIV-1 protease. The N-glyoxylyl peptide CHOCO-Pro-Ile-Val-NH2, which fulfills the specificity requirements of the MA/CA protease cleavage site together with the criteria of transition state analogue of the catalyzed reaction, was found to be a moderate competitive inhibitor although favorable interactions were visualized between its hydrated form and the catalytic aspartates using molecular modeling. Increasing the length of the peptide sequence led to compounds acting only as substrates. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00016-3